New pill shows promise for rare Gene-Driven cancers
NCT ID NCT04233567
First seen Mar 03, 2026 · Last updated May 15, 2026 · Updated 8 times
Summary
This study tested an oral drug called infigratinib in 17 adults with advanced or metastatic solid tumors that have specific FGFR gene mutations. The goal was to see if the drug could shrink or control the cancer by blocking overactive FGFR proteins. While not a cure, the treatment aims to slow disease progression and improve outcomes for patients with these rare genetic changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.